Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Roxburgh, Campbell ^a   Cook, J ^b   Dublin, N ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Adrenergic alpha antagonists therapeutic use ; Antidepressive agents therapeutic use ; Cholinergic antagonists *therapeutic use ; Dopamine uptake inhibitors therapeutic use ; Flavoxate therapeutic use ; Lidocaine therapeutic use

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; DIURETIC AGENT; DOXAZOSIN; EMEPRONIUM; EMEPRONIUM BROMIDE; FLAVOXATE; GLUCOCORTICOID; HYOSCYAMINE; IMIPRAMINE; LIDOCAINE; MONOAMINE OXIDASE INHIBITOR; OXYBUTYNIN; PETHIDINE; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; VERAPAMIL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR;

ABSENCE OF SIDE EFFECTS; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; HUMAN; MICTURITION; NAUSEA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URODYNAMICS; XEROSTOMIA; ADULT; META ANALYSIS; NOCTURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY BLADDER, OVERACTIVE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS; CHOLINERGIC ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; FLAVOXATE; HUMANS; LIDOCAINE; NOCTURIA; PARASYMPATHOLYTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE;

EID: 44949095395     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003190.pub4     Document Type: Review

References (67)

1. Cardozo 1979 {published data only} Cardozo LD, Stanton SL. An objective comparison of the effects of parenterally administered drugs in patients suffering from detrusor instability. Journal of Urology 1979;122:58-9.
2. Enzelsberger 1991 {published data only} Enzelsberger H, Schatten C, Kurz C. Comparison of emepronium bromide with intravesical administration of lidocaine gel in women with urge incontinance [Vergleeich von Emeproniumbromid mit intravesikal appliziertem Lidocain-gel bei Frauen mit Urge-Inkontinenz]. Geburtschilfe und Frauenheilkunde 1991;51(1): 54-7.
3. Frohlich 1998 {published data only} Frohlich G, Burmeister S, Weidermann A, Bulitta M. Intravesical instillation of trospium chloride, oxybutinin and verapamil for relaxation of the bladder detrusor muscle. A placebo contolled randomized clinical test [Intravesikal instillation von trospiumchlorid, oxybutinin und verapamil zur relaxation des harnblasen-detrusors. Ein placebo-kontrollierte, randomisierte klinische prufung]. Arzneimittelforschung 1998;48(5):486-91.
4. Gaudenz 1978 {published data only} Gaudenz R, Weil A. Motor urge incontinence: diagnosis and treatment. Urologia Internationalis 1980;35(1):1-12. [MEDLINE: Ref ID: 793].
5. Herbst 1970 {published data only} Herbst WP. Double blind comparison of flavoxate and propantheline as urologic antispasmodics. American Journal of Clinical Research 1970;1:65-7.
6. Meyhoff 1981 {published data only} Meyhoff HH, Gerstenberg TC, Nordling J. Placebo - the drug of choice in female motor urge incontinence?. British Journal of Urology 1983;55(1):34-7.
7. Milani 1993 {published data only} Milani R, Scalambrino S, Milia R, Sambruni I, Riva D, Pulici L, et al.Double blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. International Urogynaecology Journal 1993;4:3-8.
8. Riva 1989 {published data only} Riva D, Vigano R, Azzolini E, Colli E, Sartanj A, Scatigna M. A randomised, double-blind, crossover trial on the effecacy and tolerance of falvoxate and oxybutynin in the treatment of urge incontinence. Proceedings of the International Continence Society (ICS), 13th Annual Meeting; 1989 Sept 7-9; Ljubljiana, Slovenia. 1989:218.
9. Serels 1998 {published data only} Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin and combination therapy for the treatment of urgency and frequency in women. Neurourology & Urodynamics 1998;17(1):31-6. [MEDLINE: Ref ID: 5451].
10. Stanton 1973 {published data only} Stanton SL. A comparison of emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence. Journal of Urology 1973;110(5):529-32.
11. Takayasu 1990 {published data only} Takayasu H, Ueno A, Tsuchida S, Koiso K, Kurita T, Kawabe K, et al.Clinical evaluation of propiverine hydrochloride (P-4) for the treatment of urinary frequency - A double-blind controlled study using flavoxate hydrochloide. Nishinihon Journal of Urology 1990;52(2):248-58.
12. Wehnert 1989 {published data only} Wehnert J, Sage S. Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle (GERMAN) [Vergleichende Untersuchungen zur Wirkung von Mictonorm (Propiverin hydrochlorid) und Spasuret (flavoxat hydrochlorid) auf den Detrusor vesicae]. Zeitschrift Fur Urologie und Nephrologie 1989;82(5):259-63.
13. Aagard 1983 Aagaard J, Reuther K, Stimpel H. A comparision between the combination emepronium bromide/flavoxate and emepronium bromide in the treatment of detrusor instability. Urologia Internationalis 1983;38(3):191-2.
14. Andersen 1988 Andersen JR, Lose G, Norgaard M, Stimpel H, Andersen JT. Terodiline, Emepronium bromide or placebo for treatment of female detrusor overactivity? A randomized, double -blind cross-over study. British Journal of Urology 1988;61(4):310-3.
15. Athanasopoulos 2002 Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis I, Perimenis P, Barbalias G. Combination treatment with an a-blocker plus an anticholinergic improves quality of life in patients with bladder outflet obstruction. A prospective, randomized, controlled study (Abstract). Neurourology and Urodynamics 2002;21(4):308-9.
16. Barnick 1991 Barnick CGW, Cutner A, Cardozo LD. Detrusor instability: a double blind, dose titrated, cross-over study of Oxybutinin vesus Terodiline. Proceedings of the International Continence Society (ICS), 21st Annual Meeting; 1991 Oct 10-12; Hannover, Federal Republic of Germany. 1991:181-2.
17. Beisland 1985 Beisland HO, Fossberg E. The effects of terodiline and melardazine on sever motor urge incontinence in geriatric patients. Journal of American Geriatric Society 1985;33(1):29-32.
18. Bradley 1970 Bradley DV, Cazort RJ. Relief of bladder spasm by Flavoxate. A comparative study. Journal of Clinical Pharmacology 1970;10(1):65-8.
19. Clark 1996 Clarke B. Anticholinergic medication for the unstable bladder: Prospective trials of imipramine/propantheline versus penthienate and oxybutinin versus penthienate. International Urogynecology Journal of Pelivic Floor Dysfunction 1996;7:191-5.
20. Ekstrom 1990 Ekstrom B, Andersson KE, Mattiasson A. Intravesical administration of drugs in patients with detrusor hyperactivity. Neurourology and Urodynamics 1990;9(4):340.
21. El Bahnasawy 2002 El Bahnasawy MS, Shaaban HS, Gomha MA, Nabeeh A. Management of noctural incontinence in orthotopic ileal reservoirs using oxybutinin versus verapamil: A proscpective randomised crossover study. Journal of Urology 2002;167:86.
22. Gruneberger 1984 Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. British Journal of Obstetrics and Gynaecology 1984;91(3):275-8.
23. Homma 1997 Homma Y, Aso Y, Kawabe K, Kunamoto Y, Tsuchida M, et al.Randomized double blind study to compare clinical efficacy of temeverine and propiverine for unstable bladder and detrusor hyper-reflexia. Neurourology and Urodynamics 1997;16(5):345-6.
24. Lee 2005 *Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al.Combination treatment with propiveriene hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective randomised controlled multicentre study. Journal of Urology 1005;174:1334-8.
25. Lee KS, Kim DY, Kim JC, Kim HJ, Min KS, Park WH, et al.Combination treatment with propiverine hydrochloride and doxazosin GITS in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicentre study (ABSTRACT). Proceedings from the International Continence Society (34th Annual Meeting) and the International Urogynaecological Association; 2004 Aug 23-27; Paris. 2004; Vol. 207.
26. Lukkarinen 1987 Lukkarinen O, Grohn P, Wilen-Rosenquvist G, Juusela H, Sotarauta M, Lehtonen T. A controlled, double blind, cross over study of terodiline in motor urge incontinence. Annales Chirurgiae et Gynaecologiae 1987;76(2):121-32.
27. Robinson 1983 Robinson JM, Brocklehurst JC. Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women. British Journal of Urology 1983;55(4):371-6.
28. Sole 1984 Sole GM, Arkell DG. A symptomatic and cystomtric comparison of terodiline with emepronium in the treatment of women with frequency, urgency and incontinence. Scandanavian Journal of Urology and Nephrology Supplementum 1984;87:55-7.
29. Tammela 1999 Tammela TLJ, Mattiasson A, Chapple CR, Moller B, Bakke A, Happonen P. Short term efficacy and safety of temeverine in the treatment of bladder overactivity. A randomized clinical trial in man and women. Nerourology and Urodynamics 2000;18(4):334-5.
30. Zeegers 1987 Zeegers A, Keisswetter H, Kramer A, Jonas U. Conservative therapy of urgency and urge incontinence: a double blind clinical trial of flavoxate hydrochloride, oxybutinin chloride, emepronium bromide and placebo [Medicamenteuze behandeling van overmatige mictiedrang: Dubbel-blind onderzoek van Cetiprin, Dridase, Urispas en placebo]. World Journal of Urology 1987;5(1):57-61.
31. Shaw Leistershire MRC Incontinence Study. Ongoing study 1999.
32. 2nd ICI 2001 Abrams P, Cardozo L, Khoury S, Wein A. Incontinence: 2nd International Consultation for Incontinence. Plymouth: Health Publication Ltd, 2001:481.
33. Abrams 1988 Abrams PH, Blaivas JG, Stanton SL, Andersen JT. Standardisation of terminology of lower urinary tract function. Neurourology & Urodynamics 1988;7(5):403-27.
34. Abrams 2002 Abrams P, Cardoza L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurology & Urodynamics 2002;21(2):167-78.
35. Abrams 2003 Abrams P, Amarenco G, Bakke A, Bukzynski A, Castro-Diaz D, et al.Tamsulosin: Efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. Journal of Urology 2003;170:1242-51.
36. Alhasso 2006 Alhasso AA, McKinley J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4.
37. Andersson 2000 Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55 (Suppl 5A):51-7.
38. Andersson 2002 Andersson, KE. Potential benefits of Muscarinic M3 receptor selectivity. European Urology Supplements 2002;1(4):23-8.
39. Berghmans 2004 Berghmans B, Bo K, Hendriks E, van Kempen M, die Bie R. Electrical stimulation with non-implanted electrodes for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 3.
40. Castleden 1986 Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986;15:299.
41. Chapple 1990 Chapple CR, Parkhouse H, Gardener C, et al.Double-blind, placebo-controlled, crossover study of flavoxate in the treatment of idiopathic detrusor instability. British Journal of Urology 1990;66:491.
42. Cruz 1997 Cruz F, Guimaraes M, Silva C, et al.Suppression of bladder hyper-reflexia by intravesical instillation of resiniferatoxin. Lancet 1997;350:640.
43. Dahm 1995 Dahm TL, Ostri P, Kristensen JK, et al.Flavoxate treatment of micturiton disorders accompanying benign prostatic hypertrophy: a double-blind, placebo-controlled, multicentre investigation. Urology International 1995;55:205.
44. de Groat 1997 de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50 (6A Suppl):36-52.
45. Dmochowski 2007 Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU International 2007;99(2):247-62.
46. Duthie 2007 Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2007, Issue 3.Art. No.: CD005493. DOI:10.1002/14651858.CD005493.
47. Eri 1995 Eri LM, Tveter KJ. Alpha blockade in the treatment of syptomatic benign prostatic hyperplasia. Journal of Urology 1995;154:923.
48. Hay-Smith 2005 Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2005, Issue 3.
49. Herbison 2003 Herbison P, Arnold E. Neuromodulation with implanted electrodes for urinary storage and voiding dysfunction in adults. Cochrane Database of Systematic Reviews 2003, Issue 2.
50. Higgins 2006 Higgins JPT, Green S. Editors. Cochrane Handbook of Systematic Reviews of Interventions (Updated Sept 2006). Vol. 4.2.6, Oxford: The Cochrane Collaboration, 2006.
51. Hu 2003 Hu TW, Wagner TH, Bentkover JD, Leblanc K, Piancentini A, Stewart WF, et al.Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8.
52. Hunsballe 2001 Hunsballe JM, Djurhuus JC. Clinical options for imipramine in management of urinary incontinence. Urological Research 2001;29:118.
53. ICI 2000 Anonymous. Assessment and treatment of urinary incontinence. Scientific Commitee of the First International Consultation on Incontinence. Lancet 2000;355(9221):2153-8.
54. Kelleher 1997 Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to access the quality of life of urinary incontinent women. British Journal of Obstetrics & Gynaecology 1997;104:1374-9.
55. Kobelt 1997 Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(6A suppl):100-7.
56. Lazzeri 1997 Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. Journal of Urology 1997;158:2093.
57. Mattiasson A Mattiasson A, Ekstrom B, Andersson K-E. Effects of intravesical instillation of verapamil in patients with detrusor hyperactivity. Journal of Urology 1989;141:174.
58. Milsom 2001 Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU International 2001;87(9):760-6.
59. Nabi 2006 Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4.
60. Ouslander 1982 Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. Journal of the American Medical Association 1982;248(10):1194-8.
61. Ouslander 1986 Ouslander JG, Hepps K, Raz S, Su HL. Genitourinary dysfunction in a geriatric outpatient population. Journal of the American Geriatrics Society 1986;34(7):507-14.
62. Stewart 2001 Stewart WF, Herzog AR, Wein AJ, Abrams P, Payne C, Corey R, et al.Prevalence and impact of overactive bladder in the United States: Results from the NOBLE program. Neurology & Urodynamics 2001;20:403-22.
63. Stewart 2003 Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al.Prevalence and burden of overactive bladder in the United States. World Journal of Urology 2003;20(6):327-36.
64. Thuroff 1991 Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al.Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology 1991;145:813-6.
65. Van Kerrebroeck 1998 Van Kerrebroeck PE, Amarenco G, Thuroff JW, Madersbacher HG, Lock MT, Messelink EJ, et al.Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourlogy & Urodynamics 1998;17(5):499-512.
66. Wallace 2004 Wallace S, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 1.
67. Wein 2001 Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opinion on Investigational Drugs 2001;10:65.